Moderna (MRNA) announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in ...
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, ...
We are pleased to share additional data from our Phase 2b NAVIGATE study at ID Week which further validates CD388 as a potential once per season influenza preventative option,” said Jeffrey Stein, Ph.
JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's ...
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop ...
MedPage Today on MSN
Don't Fear Oseltamivir in Kids Hospitalized With Flu
Kids who received oseltamivir during their flu-related hospitalization were 31% less likely to be admitted to the ICU ...
With winter on the horizon, local health experts warn about a rise in respiratory illnesses. Dr. Tjaden emphasizes hygiene ...
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, Octobe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback